Foxo Technologies
Logotype for Foxo Technologies Inc

Foxo Technologies (FOXO) investor relations material

Foxo Technologies Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Foxo Technologies Inc
Q3 2026 earnings summary16 Nov, 2026

Executive summary

  • Q3 2026 revenue rose 97% YoY to $7.0M; operating income was $1.6M versus a $0.9M operating loss, and net income attributable to common operations was $101K versus a $1.9M loss.

  • Nine-month net income attributable to the business was $6.8M, largely reflecting a $9.1M noncash reversal of previously recorded share-plan compensation; excluding that reversal, management cited a $2.3M net loss.

Financial highlights

  • Q3 revenue was $7.0M, up $3.5M YoY; nine-month revenue was $16.9M, up $5.0M YoY.

  • Q3 operating expenses totaled $5.4M; interest expense was $1.4M, and net income attributable to the business was $101K.

  • Nine-month operating income was $10.1M versus an operating loss of $1.8M; net income attributable to the business was $6.8M versus a $3.0M loss.

  • Adjusted EBITDA was $1.5M for Q3 versus a $1.3M loss YoY, and $570K for nine months versus a $2.5M loss.

  • Cash was $42.7K at September 30, 2026; total debt was $17.9M and working capital deficit was $35.8M.

Outlook and guidance

  • Current revenue and operating cash flow are insufficient to fund operations over the next 12 months; additional equity or debt financing is needed to support operations and strategy.

  • The Grifols asset acquisition is now anticipated to close in Q1 2027, subject to regulatory permits and financing; $3.5M cash is due at closing, with up to $1.0M additional earn-out consideration.

  • The proposed Ludwig transactions remain unclosed and depend on Nasdaq listing approval and financing; completion would require $500K cash plus Series F preferred shares.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Foxo Technologies earnings date

Logotype for Foxo Technologies Inc
Q4 202616 Apr, 2027
Foxo Technologies
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Foxo Technologies earnings date

Logotype for Foxo Technologies Inc
Q4 202616 Apr, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Foxo Technologies Inc. is a biotechnology company focused on using epigenetic science and artificial intelligence to develop advanced health and longevity solutions. The company integrates molecular biotechnology with data analytics to offer innovative products in the life insurance and health sectors. Foxo's platform is designed to leverage epigenetic biomarkers to assess biological aging and health risks, aiming to transform underwriting processes in the life insurance industry. The company’s work in epigenetics seeks to provide more personalized insights into health and wellness. The company is headquartered in Minneapolis, Minnesota, and its shares are listed on the NYSE.